leprot Antibody

What is LEPROT and what are its key characteristics?

LEPROT (leptin receptor overlapping transcript) is a protein that belongs to the OB-RGRP/VPS55 protein family. In humans, the canonical protein consists of 131 amino acid residues with a molecular mass of approximately 14.3 kDa. Its subcellular localization is primarily in the Golgi apparatus. LEPROT is expressed at high levels in the heart and placenta, with lower expression observed in the lung, liver, skeletal muscle, kidney, and pancreas . Several synonyms exist for this protein, including OB-RGRP, OBRGRP, VPS55, leptin receptor gene-related protein, DnaJ (Hsp40) homolog, subfamily C, member 6, and LEPR. Evolutionary conservation of LEPROT is evident through identified orthologs in multiple species including mouse, rat, bovine, frog, chimpanzee, and chicken .

What are the common applications for LEPROT antibodies in research?

LEPROT antibodies are primarily utilized for the immunodetection of the leptin receptor overlapping transcript protein. The most widely employed applications include:

• Western Blot (WB): For protein expression and quantification studies

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection

• Immunocytochemistry (ICC): For cellular localization studies

• Immunofluorescence (IF): For visualization of protein expression patterns

• Immunohistochemistry (IHC): For tissue expression analysis

These applications enable researchers to investigate LEPROT expression patterns, protein interactions, and functional roles in various biological contexts.

How should researchers select the appropriate LEPROT antibody for their experiments?

Selection of an appropriate LEPROT antibody depends on several critical factors:

• Target Species Reactivity: Ensure the antibody recognizes LEPROT in your experimental species. Available antibodies show reactivity to human, zebrafish, and other species .

• Application Compatibility: Verify the antibody has been validated for your specific application (WB, ELISA, ICC, IF, or IHC).

• Antibody Format: Consider whether you need an unconjugated antibody or one with a specific conjugate/tag based on your detection system.

• Clonality: Determine whether a polyclonal or monoclonal antibody is more suitable for your research question. Polyclonal antibodies recognize multiple epitopes and may provide stronger signals, while monoclonal antibodies offer higher specificity.

• Validation Data: Review published literature and manufacturer validation data to ensure reliable performance in your experimental context.

Always include appropriate positive and negative controls in your experimental design to validate antibody specificity and performance.

What methodological approaches can accurately assess LEPROT expression in cancer tissues?

Accurate assessment of LEPROT expression in cancer tissues requires a multi-faceted approach:

• Transcriptomic Analysis: RNA-seq or qRT-PCR to quantify LEPROT mRNA levels. Studies have demonstrated that LEPROT expression is significantly aberrant in approximately 78.9% of cancer types compared to corresponding normal tissues, with downregulation in 12 cancer types and upregulation in 3 cancer types .

• Protein Detection: Immunohistochemistry using validated LEPROT antibodies on tissue microarrays can visualize spatial distribution within tumor microenvironments. Western blot analysis provides quantitative assessment of protein levels .

• Methylation Analysis: Since LEPROT expression negatively correlates with its methylation alterations, methylation-specific PCR or bisulfite sequencing can provide insights into epigenetic regulation .

• Single-cell Analysis: For heterogeneous tumors, single-cell RNA-seq can resolve cell-specific expression patterns of LEPROT within the complex tumor microenvironment.

• Spatial Transcriptomics: To understand LEPROT expression in the context of the tumor spatial architecture, especially in relation to immune infiltrates and cancer-associated fibroblasts.

When designing experiments, researchers should incorporate multiple methodologies to compensate for the limitations of individual techniques and consider tumor heterogeneity in their sampling strategy.

How can researchers effectively investigate the relationship between LEPROT and tumor microenvironment components?

Investigating LEPROT's relationship with the tumor microenvironment (TME) requires sophisticated experimental approaches:

• Immune Cell Infiltration Analysis: Use flow cytometry or immunohistochemistry with appropriate T-cell markers alongside LEPROT staining. Research has shown LEPROT expression positively correlates with immune scores in multiple cancer types including COAD, DLBC, GBM, HNSC, and LUAD .

• Co-expression Analysis: Perform correlation analyses between LEPROT and markers of specific immune cell populations. Studies have revealed remarkable correlations between LEPROT expression and CD4+, CD8+, and regulatory T cells, with particularly strong and consistent positive relationships between LEPROT and memory CD4+ T cells .

• Cancer-Associated Fibroblast (CAF) Assessment: Analyze CAF markers in relation to LEPROT expression. Evidence indicates consistent positive correlations between LEPROT expression and CAF levels across various cancer types .

• Checkpoint Molecule Expression: Investigate correlations between LEPROT and immune checkpoint molecules. PD-L1 has been shown to positively correlate with LEPROT across all cancer types studied .

• Functional Studies: Use genetic manipulation (knockdown/overexpression) of LEPROT in appropriate cell models followed by co-culture with immune cells to assess functional impacts.

The experimental approach should be tailored to specific cancer types, as LEPROT's interactions with TME components demonstrate context-dependent variations.

What are the optimal protocols for validating LEPROT antibody specificity?

Validating LEPROT antibody specificity requires a comprehensive approach:

• Knockout/Knockdown Validation:

  • Generate LEPROT knockout cell lines using CRISPR-Cas9

  • Implement siRNA-mediated knockdown of LEPROT

  • Compare antibody signals between wild-type and knockout/knockdown samples

• Overexpression Controls:

  • Transfect cells with LEPROT expression constructs

  • Compare antibody signal between transfected and non-transfected cells

• Peptide Competition Assays:

  • Pre-incubate antibody with immunizing peptide

  • Observe signal reduction in subsequent immunodetection

• Multiple Antibody Validation:

  • Compare staining patterns of different antibodies targeting distinct LEPROT epitopes

  • Confirm consistent detection patterns

• Cross-species Reactivity Testing:

  • Test antibody against LEPROT orthologs from different species

  • Confirm specificity matches claimed species reactivity

• Western Blot Molecular Weight Verification:

  • Confirm detection at the expected molecular weight (14.3 kDa for human LEPROT)

  • Investigate any unexpected bands

For maximal confidence, researchers should implement at least three different validation methods and publish detailed validation results alongside experimental findings.

How can LEPROT expression be effectively correlated with patient response to immunotherapy?

Correlating LEPROT expression with immunotherapy response requires robust methodological approaches:

• Pre-treatment Biopsy Analysis:

  • Quantify LEPROT expression using immunohistochemistry or RNA-seq

  • Establish standardized scoring systems for LEPROT expression levels

• Response Evaluation:

  • Use RECIST criteria to categorize patient responses

  • Generate receiver operating characteristic (ROC) curves to assess predictive value

• Statistical Analysis Approaches:

  • Apply logistic regression to determine odds ratios for response based on LEPROT expression

  • Use ROC curve analysis to establish optimal expression thresholds

• Context-Dependent Interpretation:

  • Analyze cancer type-specific relationships

  • Research has shown that in kidney renal clear cell carcinoma (KIRC), patients with higher LEPROT showed significantly lower response rates (0%) to PD-1 inhibitor nivolumab compared to those with low LEPROT (67%)

  • Conversely, in skin cutaneous melanoma (SKCM), patients with higher LEPROT had higher response rates (80%) compared to those with low LEPROT (40%)

• Integration with Other Biomarkers:

  • Combine LEPROT expression with established biomarkers like PD-L1 expression, tumor mutational burden, and immune cell infiltration

  • Develop multivariate models for response prediction

Researchers should acknowledge the context-dependent role of LEPROT in predicting immunotherapy response, as demonstrated by its contradictory relationships with treatment outcomes across different cancer types.

What experimental designs can elucidate LEPROT's mechanistic role in modulating immune responses?

To investigate LEPROT's mechanistic role in immune modulation, researchers should consider:

• In Vitro Co-culture Systems:

  • Establish co-cultures of cancer cells with varied LEPROT expression and immune cells

  • Measure cytokine production, T-cell activation markers, and cytotoxicity

  • Analyze changes in immune checkpoint molecule expression

• LEPROT Genetic Manipulation:

  • Create stable LEPROT knockdown and overexpression models

  • Assess consequences on immune-related signaling pathways, particularly the IL-6/JAK/STAT pathway implicated in LEPROT function

  • Measure changes in cytokine production and receptor expression

• Functional Antibody Studies:

  • Utilize neutralizing antibodies against LEPROT in appropriate models

  • Assess changes in immune cell recruitment and activation

• In Vivo Models:

  • Develop conditional LEPROT knockout mouse models

  • Analyze tumor growth, immune infiltration, and response to immunotherapy

  • Perform adoptive transfer experiments to isolate cell-specific effects

• Signaling Pathway Analysis:

  • Investigate how LEPROT modulates specific signaling cascades

  • Focus on JAK/STAT pathway components, as evidence suggests LEPROT interactions with TME may be mediated by IL-6/JAK/STAT signaling

These experimental approaches should be designed with appropriate controls and conducted across multiple cell lines or models to account for context-dependent effects observed in different cancer types.

What are the optimal conditions for using LEPROT antibodies in Western blot applications?

Optimizing Western blot protocols for LEPROT detection requires careful attention to several technical parameters:

• Sample Preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors for efficient extraction

  • For membrane-associated LEPROT, consider membrane fraction enrichment techniques

  • Heat samples at 95°C for 5 minutes in reducing SDS-PAGE loading buffer

• Gel Selection and Transfer:

  • Use 12-15% polyacrylamide gels to resolve the 14.3 kDa LEPROT protein effectively

  • PVDF membranes are preferable for low molecular weight proteins like LEPROT

  • Transfer at 100V for 1 hour or 30V overnight at 4°C

• Blocking and Antibody Incubation:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Incubate with primary LEPROT antibody at manufacturer-recommended dilutions (typically 1:500-1:2000) overnight at 4°C

  • Use secondary antibodies specific to the host species of the primary antibody

• Detection Optimization:

  • For low-abundance detection, consider using enhanced chemiluminescence substrates

  • For quantitative analysis, use fluorescently-labeled secondary antibodies and fluorescence imaging systems

• Controls:

  • Include positive control lysates from tissues known to express LEPROT (heart or placenta)

  • Use recombinant LEPROT protein as a positive control

  • Include LEPROT knockdown/knockout samples as negative controls when possible

Researchers should perform preliminary optimization experiments with various antibody concentrations and incubation times to determine optimal conditions for their specific experimental system.

How can researchers effectively analyze LEPROT expression in relation to tumor-infiltrating immune cells?

Analyzing LEPROT expression in relation to tumor-infiltrating immune cells requires sophisticated approaches:

• Multiplex Immunohistochemistry/Immunofluorescence:

  • Simultaneously stain for LEPROT and immune cell markers (CD4, CD8, CD68, FOXP3)

  • Use multispectral imaging systems for quantitative spatial analysis

  • Apply computational image analysis to quantify co-localization patterns

• Single-cell RNA Sequencing:

  • Analyze LEPROT expression at single-cell resolution

  • Cluster cells based on transcriptomic profiles

  • Correlate LEPROT expression with immune cell type-specific markers

• Computational Deconvolution Methods:

  • Apply algorithms like TIMER2, CIBERSORT, or MCP-counter to bulk RNA-seq data

  • Estimate immune cell abundance in relation to LEPROT expression

  • Research has employed multiple algorithms (Li et al., 2020; Aran et al., 2017; Newman et al., 2015) for estimating tumor-infiltrating immune cell populations in relation to LEPROT

• Flow Cytometry:

  • Isolate tumor-infiltrating lymphocytes from fresh tumor samples

  • Perform intracellular staining for LEPROT alongside surface markers for immune cell subsets

  • Quantify correlation between LEPROT levels and specific immune cell populations

• Spatial Transcriptomics:

  • Apply spatial transcriptomic technologies to map LEPROT expression in the tumor microenvironment

  • Correlate with spatial distribution of immune cells

How can LEPROT antibodies be utilized to investigate its role as a cancer biomarker?

LEPROT antibodies can facilitate biomarker investigation through:

• Tissue Microarray (TMA) Analysis:

  • Construct TMAs containing samples from multiple patients and cancer types

  • Perform immunohistochemistry with LEPROT antibodies

  • Correlate staining intensity with clinicopathological features and outcomes

  • Studies have shown LEPROT expression is significantly aberrant in 78.9% of cancer types compared to normal tissues

• Prognostic Value Assessment:

  • Stratify patient cohorts based on LEPROT expression levels

  • Perform Kaplan-Meier survival analysis

  • Calculate hazard ratios using Cox regression models

  • Research indicates LEPROT may have prognostic value in predicting patient survival in a context-dependent manner

• Liquid Biopsy Development:

  • Investigate LEPROT protein levels in circulating tumor cells or exosomes

  • Develop sensitive detection methods using LEPROT antibodies

• Multimarker Panel Integration:

  • Combine LEPROT with other established biomarkers

  • Develop multivariate prediction models

  • Test improved prognostic or predictive performance

• Immunotherapy Response Prediction:

  • Quantify pre-treatment LEPROT levels in patients receiving immune checkpoint inhibitors

  • Correlate with response outcomes

  • Generate ROC curves to determine predictive value

  • Research has shown area under the curve (AUC) values of 0.875 and 0.708 for predicting responses to PD-1 inhibitors in different cancer types

Researchers should validate findings in independent cohorts and consider cancer-specific contexts, as LEPROT's biomarker value appears to vary significantly across cancer types.

What approaches can elucidate LEPROT's role in regulating inflammatory and immune signals?

To investigate LEPROT's role in inflammatory and immune signaling:

These approaches should be implemented in relevant cellular contexts, including cancer cells, immune cells, and co-culture systems to capture the complexity of LEPROT's regulatory functions.

How can researchers effectively investigate the epigenetic regulation of LEPROT expression?

Investigating epigenetic regulation of LEPROT requires systematic methodological approaches:

• DNA Methylation Analysis:

  • Perform bisulfite sequencing of LEPROT promoter regions

  • Use methylation-specific PCR for targeted analysis

  • Apply genome-wide methylation arrays to identify differentially methylated regions

  • Research has shown LEPROT expression is negatively correlated with its methylation alterations

• Histone Modification Assessment:

  • Conduct ChIP-seq for relevant histone marks (H3K4me3, H3K27ac, H3K27me3) at the LEPROT locus

  • Correlate histone modifications with expression levels

  • Investigate the effects of histone deacetylase (HDAC) inhibitors on LEPROT expression

• Chromatin Accessibility Studies:

  • Apply ATAC-seq to identify open chromatin regions at the LEPROT locus

  • Compare accessibility between different cell types and disease states

• Transcription Factor Binding Analysis:

  • Perform ChIP-seq for transcription factors potentially regulating LEPROT

  • Validate binding using reporter assays with wild-type and mutated binding sites

• Non-coding RNA Regulation:

  • Identify miRNAs targeting LEPROT using bioinformatic prediction

  • Validate miRNA-mediated regulation through luciferase assays

  • Investigate long non-coding RNAs potentially involved in LEPROT regulation

When designing these studies, researchers should consider context-specific epigenetic regulation across different tissue types and disease states, as LEPROT expression patterns vary significantly across cancer types.

What emerging technologies might enhance the investigation of LEPROT function in cancer biology?

Several cutting-edge technologies hold promise for advancing LEPROT research:

• CRISPR Screening Approaches:

  • Genome-wide CRISPR screens to identify synthetic lethal interactions with LEPROT

  • CRISPRa/CRISPRi screens to identify regulators of LEPROT expression

  • CRISPR base editors for introducing specific mutations in LEPROT regulatory elements

• Spatial Multi-omics:

  • Integrate spatial transcriptomics with proteomics to map LEPROT expression in relation to TME components

  • Correlate with genomic alterations and epigenetic modifications at single-cell resolution

• Organoid and Patient-Derived Xenograft Models:

  • Develop cancer organoids with manipulated LEPROT expression

  • Test therapeutic interventions in humanized mouse models

  • Investigate LEPROT's role in treatment response

• Proximity Labeling Proteomics:

  • Apply BioID or APEX2 proximity labeling to identify LEPROT protein interaction networks

  • Characterize context-specific interactomes in different cell types and cancer states

• Cryo-Electron Microscopy:

  • Determine high-resolution structures of LEPROT protein complexes

  • Facilitate structure-based drug design targeting LEPROT or its interactions

These emerging technologies can provide unprecedented insights into LEPROT's molecular mechanisms and functional roles, potentially revealing new therapeutic opportunities.

How might LEPROT antibodies contribute to development of novel cancer therapeutics?

LEPROT antibodies could facilitate therapeutic development through:

• Target Validation:

  • Use antibodies to confirm LEPROT expression in patient-derived samples

  • Correlate expression with disease progression and treatment outcomes

  • Identify patient subpopulations likely to benefit from LEPROT-targeted therapies

• Therapeutic Antibody Development:

  • Generate function-modulating antibodies targeting accessible LEPROT epitopes

  • Test antibody-drug conjugates to deliver cytotoxic payloads to LEPROT-expressing cells

  • Develop bispecific antibodies linking LEPROT-expressing cells to immune effectors

• Combination Therapy Research:

  • Investigate LEPROT-targeting approaches with immune checkpoint inhibitors

  • Research suggests context-dependent roles of LEPROT in predicting responses to checkpoint inhibitors

  • Optimize sequencing and dosing of combination approaches

• Screening and Pharmacodynamic Markers:

  • Use LEPROT antibodies to identify patients for clinical trials

  • Monitor treatment effects on LEPROT expression and downstream signaling

  • Develop companion diagnostics for LEPROT-targeted therapies

• CAR-T Cell Development:

  • Explore potential for LEPROT-directed chimeric antigen receptor T-cell therapies

  • Test in preclinical models with appropriate LEPROT expression

Researchers should consider the context-dependent roles of LEPROT across different cancer types when developing therapeutic strategies, as its function appears to vary significantly between cancer contexts.